Elanco Animal Health Acquires Aratana Therapeutics

Merck Animal Health to acquire Elanco's aqua business for ~$1.3B

February 6, 2024

Veterinary

Merck Animal Health has agreed to buy Elanco Animal Health's aqua business for approximately US$1.3 billion in cash. The divestiture — which includes marketed brands, R&D projects, manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and roughly 280 commercial and manufacturing employees — will allow Elanco to focus on higher-growth pet and livestock markets and use proceeds to pay down debt.

Altano Group Acquires Avanti Equine Veterinary Partners

April 6, 2023

Veterinary

Altano Group (Altano Gruppe GmbH) has acquired Avanti Equine Veterinary Partners, adding the U.S.-based equine hospital group to its international network. Avanti—founded in 2017 with seven U.S. locations and more than 140 employees—will be integrated into Altano's expanding equine clinic platform to strengthen the group's U.S. presence and specialist capabilities.

PharmaForceIQ Acquires Aktana

January 9, 2026

Cloud & SaaS

PharmaForceIQ has acquired Aktana in an asset acquisition to integrate Aktana's AI-driven field Next-Best-Action platform into PharmaForceIQ's digital orchestration offering. The deal is intended to create an end-to-end 'optichannel-in-a-box' commercial engagement solution for life sciences, deepen PharmaForceIQ's U.S. footprint and expand reach across LATAM, APAC and EMEA; Canaccord Genuity acted as sole financial advisor.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.